Upfront Briefing

Tape Action

Instrument Last close 1D % YTD % S&P 500 6,978.6 +0.4% +1.9% Nasdaq 100 25,939.7 +0.9% +2.7% Russell 2000 2,666.7 +0.3% +7.4% XBI (Biotech ETF) 128.5 +0.5% +5.4% Nasdaq Biotech 5,995.5 +0.6% +5.1% Clinical Trials ETF (BBC) 42.8 +1.7% +11.0%

• Risk-on tape: broad equities pushed higher into a heavy earnings macro-week, with megacap strength doing a lot of the lifting.
• Healthcare cross-currents: insurers stayed under pressure on Medicare Advantage rate headlines, while biotech held up as higher-beta names bounced.
• Standout mover: Virtus LifeSci Biotech Clinical Trials ETF (BBC) led the complex — typical "high beta" behavior when sentiment improves.
• Market data: U.S. close Tue 27-Jan-2026.

The Big 3

1 Boehringer Ingelheim inks IBD bispecific deal with Simcere Boehringer Ingelheim in-licensed SIM0709, a preclinical TL1A × IL-23p19 bispecific antibody for IBD, from China’s Simcere. BI gets global rights ex-Greater China; economics include €42m upfront and up to ~€1.06B in total milestones plus royalties. Why it matters: This is Big Pharma paying real money for the same core “next-wave IBD” thesis as Caldera and others: dual blockade (TL1A + IL-23) aimed at pushing past the efficacy ceiling of single-pathway biologics. The signal isn’t just “China sourcing” — it’s that multi-target immunology is back in vogue, and pricing can re-rate TL1A/IL-23 programs across public comps and private BD processes. Source: BioSpace More: Endpoints

2 CMS selects drugs for third round of Medicare price negotiations The CMS has chosen drugs, including Lilly’s Trulicity and Gilead's Biktarvy, for the third round of Medicare price negotiations under the IRA. Why it matters: The Round 3 list is a forward de-rating event: it pulls 2028 "maximum fair price" risk into models today, re-frames terminal pricing power for Medicare-exposed brands, and can influence capital allocation (BD&L vs buybacks) as large-cap pharma reprices policy risk. Source: Endpoints More: Fierce Pharma

3 FDA lifts clinical hold on one of Intellia's gene editing studies The FDA has lifted a clinical hold on one of Intellia's Phase 3 gene editing studies, reducing uncertainty for the program. Why it matters: The hold lift reopens pivotal execution for ATTRv-PN (and supports sentiment across in vivo editing), but the fact a separate cardiomyopathy study remains on hold keeps the safety/monitoring debate alive — investors will watch for protocol changes, re-enrollment pace, and whether any label ambition narrows. Source: Endpoints More: BioPharma Dive; BioSpace

Everything Else that broke

• CMS proposes incentives for hospitals to buy US-made drugs. — Endpoints
• ICYMI: Roche moves Carmot’s CT-388 into Phase 3 — Street will focus on durability vs Novo/Lilly and whether trial design supports differentiated long-term positioning. — BioPharma Dive
• Cardiff Oncology reports mixed Phase 2 data, execs depart. — Endpoints
• FDA approves Darzalex Faspro + VRd for transplant-ineligible newly diagnosed multiple myeloma. — FDA; J&J
• Lisata reclaims China rights to its lead solid-tumor candidate ahead of its acquisition by Kuva Labs. — Fierce Biotech

Deal Flow

M&A / BD&L

• Boehringer Ingelheim inks IBD bispecific deal with Simcere (details above). — BioSpace
• Insilico Medicine signs $120M drug discovery pact with Qilu Pharma. — Endpoints

VC / Private Financings

• TRex Bio raises $50M Series B extension for eczema drug. Syndicate includes Janus, Alexandria, Lilly, Pfizer, JJDC and SV Health. — BioPharma Dive
• Sensorion raises €60M, including a €20M strategic investment from Sanofi. — Yahoo

IPOs / Follow-Ons

• Altimmune prices a $75M registered direct offering of common stock. — PR

Academic Corner

• Single-cell proteomic landscape of the developing human brain. — Nature Biotech
• Humoral IgG1 responses to tumor antigens underpin clinical outcomes in immune checkpoint blockade. — Nature Medicine